Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease

 Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease

Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease

Shots:

  • Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD. The termination allows Synlogic to deploy its expertise in strain engineering, quantitative biology, regulatory, and manufacturing of living medicines for expanding its wholly GI-based program portfolio to include IBD
  • Regaining WW rights to develop treatments for IBD allows Synlogic to expand its efforts in exploring new areas of biology and potential partnerships
  • Under the terms of the original 2015 agreement, AbbVie had an exclusive option to acquire a Synlogic’s subsidiary (IBDCo) while in exchange Synlogic IBDCo received $2M as upfront and up to $16M upon the achievement of milestones

Click here ­to­ read full press release/ article | Ref: Synlogic  | Image: Synlogic

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post